Originally published In Press as doi:10.1074/jbc.M000142200 on March 30, 2000
J. Biol. Chem., Vol. 275, Issue 23, 17596-17604, June 9, 2000
Regulation and Intracellular Trafficking Pathways of the
Endothelin Receptors*
Toril
Bremnes
,
Joachim D.
Paasche
,
Anja
Mehlum
,
Cecilie
Sandberg
,
Bjørn
Bremnes§, and
Håvard
Attramadal
¶
From the
Merck Sharp & Dohme Cardiovascular Research
Center and Institute of Surgical Research, University of Oslo, The
National Hospital, 0027 Oslo, Norway and the § Department of
Biochemistry, The Norwegian Radium Hospital, 0310 Oslo, Norway
Received for publication, January 10, 2000, and in revised form, March 15, 2000
 |
ABSTRACT |
The effects of endothelin (ET) are mediated via
the G protein-coupled receptors ETA and
ETB. However, the mechanisms of ET receptor
desensitization, internalization, and intracellular trafficking are
poorly understood. The aim of the present study was to investigate the
molecular mechanisms of ET receptor regulation and to characterize the
intracellular pathways of ET-stimulated ETA and
ETB receptors. By analysis of ETA and
ETB receptor internalization in transfected Chinese hamster
ovary cells in the presence of overexpressed
ARK,
-arrestin-1,
-arrestin-2, or dynamin as well as dominant negative mutants of
these regulators, we have demonstrated that both ET receptor subtypes
follow an arrestin- and dynamin/clathrin-dependent mechanism of internalization. Fluorescence microscopy of Chinese hamster ovary and COS cells expressing green fluorescent protein (GFP)-tagged ET receptors revealed that the ETA and
ETB subtypes were targeted to different intracellular
routes after ET stimulation. While ETA-GFP followed a
recycling pathway and colocalized with transferrin in the
pericentriolar recycling compartment, ETB-GFP was targeted
to lysosomes after ET-induced internalization. Both receptor subtypes
colocalized with Rab5 in classical early endosomes, indicating that
this compartment is a common early intermediate for the two ET
receptors during intracellular transport. The distinct intracellular
routes of ET-stimulated ETA and ETB receptors
may explain the persistent signal response through the ETA
receptor and the transient response through the ETB
receptor. Furthermore, lysosomal targeting of the ETB
receptor could serve as a biochemical mechanism for clearance of plasma
endothelin via this subtype.
 |
INTRODUCTION |
The multiple physiological effects of the vasoactive peptide
hormone endothelin (ET)1 (1)
are mediated via the G protein-coupled receptors (GPCRs) ETA and ETB (2). ET-1 acts directly on
ETA receptors expressed on vascular smooth muscle cells to
mediate a long lasting vasoconstrictive response. The prolonged
response through agonist-stimulated ETA receptors has also
been demonstrated in cultured cells expressing this receptor (3).
Although the ETB receptor may also mediate vasoconstriction
(4, 5), this subtype, which is primarily situated at the plasma
membrane of endothelial cells, is first of all considered to cause
transient NO-mediated vasodilatation (6).
Circulating ET-1 is rapidly removed from the plasma, and current
evidence suggests that the ETB receptor is important for clearance of plasma ET-1 both under normal conditions (7, 8) and in
pathological conditions with increased plasma levels of ET-1 (9). The
mechanism of ETB receptor-mediated clearance of ET-1 is not
known, but one hypothesis is that receptor-bound ET-1 is targeted to
degradation in the cell.
The general model for regulation of GPCR desensitization and
internalization is primarily based on studies of the prototypic
2-adrenergic receptor (10-15). According to this model,
agonist-activated receptors are phosphorylated by GPCR kinases (GRKs),
followed by binding of arrestin and initiation of receptor
internalization through a clathrin/dynamin-dependent
mechanism (16-18). Both the ETA and the ETB
receptors have been shown to undergo rapid desensitization (19, 20) and
to internalize with similar kinetics (3, 21) in transfected cell
models. However, neither the molecular mechanisms of ETA
and ETB receptor regulation nor their intracellular
trafficking pathways are known. Addressing these issues may not only
elucidate the mechanisms of ET receptor regulation but may also provide the molecular basis for the distinct physiological responses mediated by the two receptors.
We have used transfected Chinese hamster ovary (CHO) and COS cells as
model systems for studying ET receptor internalization and
intracellular trafficking. To facilitate the latter, we have constructed chimeric ET receptors with a C-terminal fusion of green
fluorescent protein (GFP). The chimeric ET receptors were found to have
similar functional properties as their wild type counterparts, making
them appropriate tools for this study. We found that although both the
ETA and the ETB receptors utilize an arrestin
and dynamin/clathrin-dependent mechanism of
internalization, they follow different intracellular pathways upon ET
stimulation. Based on our data, we suggest that different intracellular
trafficking routes may be an important mechanism underlying the
distinct physiological responses mediated by the ETA and
ETB receptors.
 |
EXPERIMENTAL PROCEDURES |
Plasmid Constructs--
The human ETA and
ETB receptors in pME18sf (22) were provided by Prof. T. Masaki (Kyoto University, Japan). An EcoRI-NotI fragment of pME18sf-ETA was subcloned into pcDNA1 for
expression in CHO cells. For subcloning of the ETB
receptor, PCR-directed mutagenesis was used to introduce a
HindIII site in front of the start codon, followed by
cloning of the fragments HindIII-EcoRV and
EcoRV-XbaI into pcDNA1. The cDNAs of
hemagglutinin (HA) epitope-tagged dynamin WT and dynamin K44A mutant
(23) in pRK5 were gifts from Dr. C. van Koppen (University of Essen,
Germany). Rat
-arrestin-1 and
-arrestin-2 were in pCMV5 (24).
Their respective mutants V53D and V54D in pcDNA1 were from Dr.
M. G. Caron (Duke University, Durham, NC). Rat
ARK1 in pCMV5
and
ARK1-CT in pRK5 were gifts from Dr. R. J. Lefkowitz and Dr.
W. Koch, respectively (Duke University). MycRab5 Q79L in pcDNA1 and
the human transferrin receptor (TfR) in pGEM1-T7 were from Dr. H. Stenmark (the Norwegian Radium Hospital, Oslo). An EcoRI
digest of pGEM1-hTfR was subcloned into pcDNA1 for expression in
CHO cells.
Construction of ETA-GFP and ETB-GFP
Chimeric Receptors--
pEGFPN1 (CLONTECH), an
expression vector containing the coding sequence of a modified form of
GFP from Aequorea victoria was chosen for cloning and
expression of the ET receptor fusion proteins. For construction of
ETA-GFP, PCR-directed mutagenesis was performed on the
template pBS-ETA using the oligonucleotide primers
5'-ctaagcaatcatgtggatg-3' and 5'-gcggatcccggttcatgctgtccttatggctgc-3'
to remove the stop codon of ETA and introduce a
BamHI restriction site. The
HindIII-KpnI and
KpnI-BamHI fragments of ETA were
subsequently inserted into pEGFPN1 to create a receptor fusion protein
with GFP linked to the C-terminal cytoplasmic tail. Similarly, for
construction of ETB-GFP, PCR was performed on the template
pcDNA1-ETB with the primers
5'-gatcccaatagatgtgaac-3'and 5'-cgcggatcccgagatgagctgtatttattactgg-3' to remove the stop codon and introduce a BamHI site. The
HindIII-BamHI fragment of ETB was
subsequently cloned into the pEGFPN1 expression vector.
Cell Lines and Transfections--
CHO K1 cells (ATCC no. CCL-61)
were maintained in Ham's F-12 Kaighn's modified medium (Life
Technologies, Inc.) supplemented with 10% fetal bovine serum (Bio
Whittaker) and 50 µg/ml garamycin in a humidified atmosphere
containing 5% CO2 at 37 °C. COS-7 cells (ATCC no.
CRL-1651) were propagated in Dulbecco's modified Eagle's medium
containing 10% fetal bovine serum and garamycin as above. Cells were
grown to 40-60% confluency in 35-mm wells before transient transfection using LipofectAMINE reagent (Life Technologies) according to the manufacturer's instructions. For immunofluorescence
experiments, cells were plated onto glass coverslips in 24-well plates
before LipofectAMINE transfection. Rab5 Q79L was expressed in CHO cells using the vaccinia T7 expression system as described by Stenmark et al. (25).
Kinetics of 125I-ET-1
Internalization--
Internalization of ETA and
ETB receptors was determined using 125I-ET-1
(Amersham Pharmacia Biotech). Twenty-four hours after transfection, the
cells were placed on ice, washed, and preincubated in binding buffer
(Hanks' balanced salt solution with 20 mM Hepes, pH 7.4, 0.2% BSA, and 0.1% glucose) before binding of 50 pM
125I-ET-1 in binding buffer for 3 h at 4 °C. The
cells were washed extensively in ice-cold PBS to remove unbound
radioligand before incubation in prewarmed binding buffer at 37 °C
for various time points. The cells were subsequently treated for 2 × 10 min at 4 °C with 0.5 M acetic acid, 0.15 M NaCl, pH 2.5 (ETA), or 50 mM
glycine-HCl, 0.5 M NaCl, pH 2.5 (ETB) to strip
off surface-bound radioligand. Acid-stripped cells were then lysed for
10 min in 1 M NaOH before the fraction of surface-bound
ET-1 in the acid wash and the fraction of internalized ET-1 in the
lysate were determined by
-spectrometry. Internalized receptor was
calculated as the fraction of radioactivity not associated with the
cell surface after acid wash. Nonspecific binding was determined using excess of unlabeled ET-1 (Peninsula Laboratories).
Western Blot Analysis--
To verify the expression of the
different GPCR regulators and their respective mutants, we performed
Western blot analysis of samples from the transiently transfected CHO
cells. Protein samples were prepared by harvesting cells in 10 mM Tris-HCl, pH 7.4, 1% SDS, 1 mM
Na3VO4. 25 µg of protein was loaded per well for SDS-polyacrylamide gel electrophoresis followed by electroblotting onto polyvinylidene difluoride membranes. For
ARK1 and
ARK1-CT, we used TBS (50 mM Tris-HCl, pH 8.0, 100 mM
NaCl) with 0.1% Tween 20, 2.5% dry milk powder, and 2.5% BSA for
blocking and antibody incubations. Primary antibody was
affinity-purified polyclonal anti-GRK2 (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA) used at 1:300. As secondary antibody, we used
horseradish peroxidase-conjugated donkey anti-rabbit IgG (Amersham
Pharmcia Biotech) diluted at 1:3000. For
-arrestins and dynamin, we
used PBS with 0.05% Tween 20, 2.5% dry milk powder, and 2.5% BSA for
blocking and antibody incubations. To detect
-arrestins, we used
polyclonal antisera raised against the respective proteins (24) and
horseradish peroxidase-conjugated donkey anti-rabbit secondary
antibody. Hemagglutinin-tagged dynamin was detected with a monoclonal
anti-HA (12CA5) antibody (Babco) diluted 1:1000 and a horseradish
peroxidase-conjugated sheep anti-mouse Ig secondary antibody (1:3000).
The blots were developed using enhanced chemiluminescence (ECL) as
recommended by the manufacturer (Amersham Pharmacia Biotech).
Phosphorylation of GFP Fusion Proteins--
Transiently
transfected CHO cells (35-mm wells) expressing ETA-GFP or
ETB-GFP with or without coexpression of
ARK1 or
ARK2 were labeled with 500 µCi/well of [32Pi]
(NEN Life Science Products) in phosphate-free Dulbecco's modified Eagle's medium for 1 h at 37 °C. To promote receptor
activation/phosphorylation, the cells were subsequently incubated with
ET-1 (1 µM) for 10 min. After ET-1 stimulation, the cells
were rapidly chilled on ice, washed twice in PBS, and lysed for 30 min
in ice-cold radioimmune precipitation buffer containing protease
inhibitors (150 mM NaCl, 50 mM Tris-HCl, pH
8.0, 5 mM EDTA, 1% Nonidet P40, 0.5% deoxycholate, 0.1%
SDS, 10 mM NaF, 10 mM Na2
pyrophosphate, and protease inhibitors (0.1 mM
phenylmethylsulfonyl fluoride, 10 µg/ml benzamidine, 10 µg/ml
leupeptin, 5 µg/ml aprotinin, and 1 µg/ml pepstatin A)). Cell
lysates were cleared by centrifugation for 10 min at 10,000 × g (4 °C), and immunoprecipitation of labeled receptors
was performed using a rabbit polyclonal peptide antibody against GFP
(CLONTECH) and protein A-agarose (Upstate
Biotechnology Inc.). Beads with antibody-antigen complexes were washed
three times in radioimmune precipitation buffer and subsequently
denatured at 65 °C in 2× SDS loading buffer (Laemmli) containing
5% urea and 5%
-mercaptoethanol. Immunoprecipitated proteins were
separated by SDS-polyacrylamide gel electrophoresis followed by
autoradiography on phosphor screens and PhosphorImager analysis
(Molecular Dynamics, Inc., Sunnyvale, CA).
Phosphoinositide Hydrolysis--
Twenty-four hours after
transfection, CHO cells (35-mm wells) were labeled with 2 µCi/ml
myo-[3H]inositol in Dulbecco's modified
Eagle's medium without inositol (Life Technologies) for 24 h. The
cells were subsequently washed and treated with 20 mM LiCl
in medium with or without 0.1 µM ET-1 for different time
points, with six parallels at each time point. The reactions were
terminated by adding 1 ml/well of 0.4 M perchloric acid for
5-10 min at room temperature. The samples (0.8 ml) were neutralized
with 0.4 ml of 0.72 M KOH, 0.6 M
KHCO3 and centrifuged for 15 min at 3000 rpm. The
supernatants were diluted in distilled H2O (1:4), and total
inositol phosphates were separated by anion exchange chromatography on
Dowex AG1-8x columns (Bio-Rad). The columns were washed twice with 10 ml of distilled H2O to remove free inositol, followed by
elution of total inositol phosphates with 7.5 ml of 1 M
ammonium formate, 0.1 M formic acid and determination of
3H by liquid scintillation counting.
Radioligand Binding--
Radioligand binding was performed on
membrane preparations according to Elshourbagy et al. (26)
with the modifications outlined below. CHO cells transiently
transfected with receptor were washed in ice-cold PBS and harvested in
25 mM Tris-HCl, 2 mM EDTA, pH 8.0, containing
protease inhibitors (30 µg/ml benzamidine, 100 µM
phenylmethylsulfonyl fluoride). The cells were homogenized on ice using
a Dounce glass homogenizer, followed by centrifugation at 50,000 × g for 15 min. The membrane pellets were resuspended in 25 mM Tris-HCl, pH 7.5, 2 mM EDTA, 100 mM NaCl, 1 mg/ml BSA, and protease inhibitors as above, and
saturation binding analysis was performed for 1 h at 37 °C
using 2-1000 pM 125I-ET-1 in the absence
(total binding) or presence (nonspecific binding) of a 100-fold excess
of unlabeled ET-1. For the binding experiments, we used 1 µg of
membrane protein in a total volume of 75 µl per sample. The samples
were filtered through Whatman GF/C filters presoaked with 0.05% BSA to
remove unbound ligand. After three washes in 0.5 M NaCl,
the filters were subjected to
-spectrometric analysis.
Analysis of Internalized ETA-GFP and
ETB-GFP by Fluoresence Microscopy--
For analysis of ET
receptor trafficking, transfected cells grown on glass coverslips were
placed on ice, washed, and preincubated for 10 min with Hanks'
balanced salt solution-Hepes before binding of 0.4 µM
ET-1 in binding buffer (Hanks' balanced salt solution-Hepes with 0.2%
BSA and 0.1% glucose) for 1 h at 4 °C. Unbound ligand was
removed by washing in Hanks' balanced salt solution-Hepes, and the
cells were subsequently incubated at 37 °C for various periods of
time. The cells were fixed in 4% paraformaldehyde before mounting onto
object glasses using Mowiol (Hoechst). The specimens were analyzed
using either a Zeiss Axiovert-100 fluorescence microscope or a Leica
TCS laser-scanning microscope with a 100 × 1.3 oil immersion
objective. Images were processed and overlaid using Photoshop 4.0 and
the Metamorph Imaging System.
Uptake of Fluorescent Probes and Staining of Intracellular
Antigens for Fluorescence Microscopy--
For the transferrin (Tf)
uptake experiments, cells were cotransfected with ET receptor and the
human TfR. Cells were pretreated with 10 µg/ml cycloheximide for 30 min before ET-1 binding was performed as described above. During ET-1
internalization at 37 °C, tetramethylrhodamine-conjugated Tf
(Molecular Probes, Inc., Eugene, OR) was added to the cells in binding
buffer at a concentration of 25 µg/ml for labeling of the
pericentriolar recycling compartment. The cells were washed in ice-cold
PBS before fixation in 4% paraformaldehyde and mounting onto object
glasses for fluorescence microscopy analysis.
Labeling of lysosomes in CHO cells was done overnight with 0.2 mg/ml
Texas Red-conjugated dextran (Molecular Probes) followed by a 2-h chase
period at 37 °C to wash the probe out of early and late endosomes.
To analyze receptor trafficking in this experiment, ET-1 was
internalized for various periods of time during the 2-h chase period.
The cells were fixed and mounted as described above and subjected to
fluorescence microscopy.
For staining of intracellular antigens, the cells were permeabilized in
PBS containing 0.1% Triton X-100 after paraformaldehyde fixation. Free
aldehyde groups were quenched by adding a few drops of 1 M
glycine, pH 8.5, to the PBS wash prior to the permeabilization step.
10% fetal bovine serum in PBS was added for 5 min at room temperature
for blocking before antibody incubation. Primary and secondary
antibodies were diluted in PBS to a concentration recommended by the
manufacturer or as experienced to give optimal results. Between
antibody incubations, the cells were extensively washed in PBS.
Immunofluorescence staining of endogenous
COP in CHO cells was done
using a rabbit antiserum and a Texas Red-conjugated goat anti-rabbit
secondary antibody (Southern Biotechnology). Late endosomes and
lysosomes in COS cells were visualized using a rabbit antiserum against
human LAMP-2 and an Alexa594-conjugated goat anti-rabbit secondary
antibody (Molecular Probes). Staining of MycRab5 Q79L expressed using
the vaccinia T7 system was performed using a mouse anti-Myc antibody
followed by a rhodamine-labeled goat anti-mouse secondary antibody
(both from Dr. H. Stenmark, the Norwegian Radium Hospital, Oslo).
 |
RESULTS |
Mechanisms of ETA and ETB Receptor
Internalization in CHO Cells--
To investigate the effects of
different regulators of GPCR on ET receptor internalization, CHO cells
were transiently transfected with ETA or ETB
receptors alone or together with wild type or mutant forms of
ARK1
(GRK2),
-arrestin-1,
-arrestin-2, and dynamin. Receptor
internalization was determined by 125I-ET-1 uptake as
described under "Experimental Procedures." Internalized receptor at
each time point was calculated as the fraction of radioactivity left
after removing surface-bound radioligand with low pH wash.
ETA and ETB receptors were both rapidly
internalized upon agonist stimulation, reaching 25% within 10 min
(Fig. 1), which is consistent with
previous reports on ET receptor internalization (3, 21).

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 1.
Effects of wild type and mutant
ARK1, -arrestins, and
dynamin on ET receptor internalization. A-H
demonstrate internalization kinetics of the ETA receptor
(left panels) or ETB receptor (right
panels) in CHO cells cotransfected with various regulator proteins
as indicated below. Expression of regulator proteins was determined by
Western blot analysis as described under "Experimental Procedures."
125I-ET-1 was bound to the transfected cells for 3 h
at 4 °C, and unbound ligand was removed by extensive washing.
Internalization was performed at 37 °C for different periods of
time. At each time point % internalized was calculated as
the fraction of radioactivity not associated with the cell surface
(acid-resistant activity). Data are mean ± S.D. of three parallel
wells and representative of at least three separate experiments.
A and B, CHO cells transfected with ET receptor
alone ( ) and ET receptor together with ARK1 WT ( ) or
ARK1-CT ( ). C-F, CHO cells transfected with ET
receptor alone ( ) and ET receptor together with -arrestin-1 ( ,
C and D), -arrestin-2 ( , C and
D), -arrestin-1 V53D ( , E and
F), or -arrestin-2 V54D ( , E and
F). G and H, CHO cells transfected
with ET receptor alone ( ) and ET receptor together with dynamin WT
( ) or dynamin K44A ( ).
|
|
ARK1-CT, a C-terminal fragment of
ARK1 containing a G
binding domain (pleckstrin homology domain) (27), was cotransfected with the ET receptors to competitively inhibit the actions of endogenous
ARK. We found that
ARK1-CT significantly decreased the
rate of ETA receptor internalization (Fig. 1A).
No effect was observed on internalization of the ETB
subtype in this experimental condition (Fig. 1B), although a
small inhibition was discernible at higher levels of
ARK1-CT
overexpression (not shown). Coexpression of
ARK1 wild type had no
effect on the internalization kinetics of any of the receptor subtypes
(Fig. 1, A and B). However, as shown in the
Western blots of Fig. 1, nontransfected CHO cells also express
significant amounts of
ARK1.
-Arrestin-1 and
-arrestin-2 are nonvisual arrestins shown to
interdict signaling through GPCRs phosphorylated by GRK (24). Arrestin
subsequently targets the receptor to clathrin-mediated endocytosis by
binding to the clathrin heavy chain and the
-adaptin subunit of the
AP-2 adaptor (15, 28). As shown in Fig. 1, C and
D, internalization of both ET receptor subtypes increased when overexpressing the wild type
-arrestin-1 and
-arrestin-2. The effect appeared to be more pronounced on internalization of the
ETA receptor than the ETB receptor. This
observation was substantiated by ET receptor internalization
experiments in CHO cells where transfection of increasing amounts of
-arrestin-1 or
-arrestin-2 cDNA was associated with smaller
increments of internalization of ETB than of
ETA (data not shown). Nevertheless, these results show that
both receptors are recognized by arrestins and can be recruited to an
arrestin-mediated pathway of internalization.
-Arrestin-1 V53D and
-arrestin-2 V54D are dominant negative mutants of
-arrestin-1 and
-arrestin-2, respectively, which competitively inhibit endogenous
arrestin binding to clathrin (14). When the V53D and V54D mutants were
cotransfected with the ET receptors in CHO cells, the internalization
rate was significantly reduced for both receptor subtypes (Fig. 1,
E and F), demonstrating that endogenous arrestins
of the CHO cells are involved in regulation of the transfected ET receptors.
Cotransfection of the GTPase-deficient mutant dynamin K44A (23, 29)
substantially inhibited internalization of the ETA and
ETB receptors, suggesting that both receptors are subjected to endocytosis through clathrin-coated pits (Fig. 1, G and
H). As shown, overexpression of wild type dynamin did not
affect ET receptor internalization. Impaired endocytosis of both ET
receptor subtypes was also observed after incubation in hyperosmotic
sucrose and upon potassium depletion (not shown), i.e.
methods demonstrated to inhibit clathrin-mediated endocytosis (30, 31).
Taken together, our results implicate a role for arrestins and a
dynamin/clathrin-dependent pathway in regulation of ET
receptor endocytosis.
Functional Characteristics of the ETA-GFP and
ETB-GFP Fusion Proteins--
Redistribution of ET
receptors from the plasma membrane to intracellular locations has
previously been observed (21, 32), but neither the receptor-containing
compartments nor the intracellular trafficking pathways of the
receptors have been characterized. To delineate the intracellular
trafficking pathways of the ETA and ETB
receptors, we employed ET receptor-GFP fusion proteins for
visualization of receptors during endocytosis. Chimeric ETA and ETB receptors with GFP fused to the cytoplasmic tail
were constructed as described under "Experimental Procedures."
Radioligand binding studies of membrane preparations from CHO cells
transiently transfected with ETA-GFP or ETB-GFP
demonstrated pharmacological properties very similar to the wild type
receptors (Table I). Furthermore,
internalization of 125I-ET-1 in CHO cells expressing
ETA-GFP or ETB-GFP showed that both subtypes
were rapidly internalized with kinetics similar to the wild type
ETA and ETB receptors (Fig.
2, A and B). The capacity of ETA-GFP and ETB-GFP to mediate
ET-1-induced phosphatidyl inositol hydrolysis and inositol phosphate
accumulation was also examined, and as shown in Fig. 2, C
and D, the chimeric receptors displayed similar efficacies
as compared with their wild type counterparts.
View this table:
[in this window]
[in a new window]
|
Table I
Radioligand binding characteristics of wild type and chimeric ET
receptors
The properties of ET-1 binding, including the number of binding sites,
were determined in CHO cells transiently transfected with ETA
WT, ETA-GFP, ETB WT, or ETB-GFP receptors.
Binding of 125I-ET-1 was performed on membranes as described
under "Experimental Procedures" to determine the equilibrium
dissociation constants (Kd) and the maximal binding
(Bmax) for the different receptors. All data
represent a mean of three parallels, presented with 95% confidence
intervals (GraphPad Prism).
|
|

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 2.
Functional characteristics of chimeric
ETA-GFP and ETB-GFP receptors expressed in CHO
cells. Upper panels, internalization kinetics of
125I-ET-1 in CHO cells transiently transfected with wild
type ET receptors or chimeric receptors with C-terminal fusion of GFP.
A, internalization of ETA WT receptor ( )
compared with ETA-GFP ( ); B, internalization
of ETB WT receptor ( ) compared with ETB-GFP
( ). 125I-ET-1 uptake was performed as described in the
legend to Fig. 1 and under "Experimental Procedures." As shown, the
internalization patterns were similar for the GFP-tagged and the wild
type ET receptors. Lower panels, C, inositol
phosphate accumulation in CHO cells transiently transfected with
ETA WT receptor ( , ET-1, 0.1 µM; ,
basal) or ETA-GFP ( , ET-1, 0.1 µM; ,
basal). , untransfected cells stimulated with ET-1 (0.1 µM). D, inositol phosphate accumulation in CHO
cells transfected with ETB WT receptor ( , ET-1, 0.1 µM; , basal) or ETB-GFP ( , ET-1, 0.1 µM; , basal). , untransfected cells, as in
C. Cells were labeled with
myo-[3H]inositol as described under
"Experimental Procedures" and incubated with LiCl in the presence
or absence of ET-1 (0.1 µM) for the time points
indicated. Total inositol phosphates were separated by ion exchange
chromatography using Dowex AG1-8x and determined by liquid
scintillation counting. As shown, the chimeric ET receptors showed the
same pattern of inositol phosphate accumulation as their wild type
counterparts.
|
|
To investigate the ability of ETA-GFP and
ETB-GFP to undergo agonist-induced phosphorylation, we
performed whole cell phosphorylation assays. Transfected CHO cells
metabolically labeled with inorganic phosphate,
32Pi, were incubated for 10 min in the absence
or presence of 1 µM ET-1. Immunoprecipitation of the
receptors using an antibody directed against GFP was followed by
SDS-polyacrylamide gel electrophoresis and detection of phosphorylated
receptors by laser scan PhosphorImager analysis as described under
"Experimental Procedures." As shown in Fig.
3, phosphorylation of both
ETA-GFP (migrating at Mr
80,000-110,000) and ETB-GFP (migrating at
Mr 70,000-85,000) was induced by ET-1 stimulation and could be detected both in the absence and presence of
coexpressed
ARK1 or
ARK2. Two distinct bands underwent
significant agonist-dependent phosphorylation both in
ETA- GFP- and ETB-GFP-transfected cells in
accordance with previous findings for wild type ET receptors (20).
Altogether, our results show that attachment of GFP to the cytoplasmic
tail of the ET receptors does not alter the functional characteristics
of the receptors.

View larger version (55K):
[in this window]
[in a new window]
|
Fig. 3.
ET-1 induced phosphorylation of
ETA-GFP and ETB-GFP. CHO cells transfected
with chimeric ETA-GFP (A) or ETB-GFP
(B) alone or together with ARK1 (GRK2) or ARK2 (GRK3)
were metabolically labeled with 32Pi and
incubated with or without ET-1 (1 µM) for 10 min as
described under "Experimental Procedures." Cell lysates were
prepared in radioimmune precipitation buffer, and immunoprecipitation
of labeled receptors was performed with a polyclonal peptide antibody
directed against GFP. After SDS-polyacrylamide gel electrophoresis,
phosphorylated receptors were detected by autoradiography and
PhosphorImager analysis. The arrows indicate the
phosphorylated receptor bands. Molecular mass markers (83 and 62 kDa)
are indicated at the left. The autoradiograms are
representative of three independent experiments.
|
|
Characterization of the Intracellular Trafficking Pathways of
ETA-GFP and ETB-GFP--
ETA-GFP
and ETB-GFP were transiently transfected into CHO cells to
investigate the intracellular routes of the receptors after agonist
stimulation. In the absence of agonist, both receptors were localized
at the plasma membrane (Fig. 4,
A and C). To study the intracellular ET receptor
trafficking pathways, CHO cells were incubated with ET-1 (0.4 µM) for 1 h at 4 °C. Unbound ligand was removed
by extensive washing, and internalization of the receptors was
subsequently studied at 37 °C for different periods of time. Since
endocytosis does not occur at 4 °C, receptor internalization is
synchronized once the medium is changed to 37 °C. Within a few
minutes, both ETA-GFP and ETB-GFP could be
detected in intracellular compartments. As shown by immunofluorescence
microscopy, strikingly different patterns were observed for the two
receptor subtypes. While the ETB receptor was localized to
punctate endosome-like structures throughout the cytoplasm 15 min after
initiation of internalization, the ETA receptor was found
to accumulate in a distinct spotlike structure near the nucleus after
15 min (Fig. 4, B and D). The perinuclear
localization of ETA-GFP is typical for the pericentriolar
recycling compartment, a tightly clustered accumulation of tubules and
vesicles located near the centrioles and the Golgi apparatus (33),
which serves as a compartment for controlling recycling of membrane
proteins (34). To investigate the nature of the compartment containing
ETA-GFP, CHO cells transfected with ETA-GFP
were stained for immunofluorescence using an antiserum against
COP,
a subunit of the Golgi-stack coatomer complex (35), and a Texas
Red-conjugated secondary antibody after 15 min of ET-mediated receptor
internalization. Cycloheximide was included during the incubations to
prevent accumulation of newly synthesized ETA-GFP in the
Golgi apparatus. As shown in Fig. 5, the
red fluorescent
COP staining (Fig. 5B) was distinct from
the intracellular green fluorescence representing ETA-GFP
(Fig. 5A), since no yellow color due to colocalization could
be seen in the overlaid pictures (Fig. 5C). Repeated
analysis always demonstrated that the perinuclear ETA-GFP-containing compartment was close to, but not
overlapping with, the Golgi stacks.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 4.
ET-1-induced internalization of
ETA-GFP and ETB-GFP in CHO cells. CHO
cells on cover glasses were transiently transfected with
ETA-GFP (A and B) or
ETB-GFP (C and D) and visualized by
fluorescence microscopy either untreated (A and
C) or 15 min after the initiation of ET-1 internalization
(B and D). ET-1 (0.4 µM) was bound
to the cells for 1 h (4 °C), and internalization was
subsequently performed at 37 °C as described under "Experimental
Procedures." After internalization, cells were fixed in
paraformaldehyde at 4 °C and investigated by confocal laser-scanning
microscopy. Note that ETA-GFP entered a perinuclear
compartment after internalization (B), whereas
ETB-GFP entered punctate endosome-like structures
throughout the cytoplasm (D).
|
|

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 5.
Localization of ETA-GFP but not
ETB-GFP to the pericentriolar recycling compartment in CHO
cells. Upper panels, A-C, after binding at
4 °C, ET-1 was internalized at 37 °C for 15 min in CHO cells
expressing ETA-GFP. After paraformaldehyde fixation and
permeabilization in 0.1% Triton X-100, Golgi stacks were visualized by
staining with an anti- COP antiserum followed by a Texas
Red-conjugated goat anti-rabbit secondary antibody. The overlay
(C) shows no colocalization between ETA-GFP and
COP. Middle and lower panels, D-I,
ETA-GFP (D-F) or ETB-GFP
(G-I) was expressed in CHO cells together with the TfR. At
the start of the 15-min ET-1 internalization period, Rh-Tf was added to
the cells for labeling of the pericentriolar recycling compartment. The
overlays show that ETA-GFP (F) but not
ETB-GFP (I) colocalized with Rh-Tf in the
recycling compartment.
|
|
At steady state, transferrin has been shown to accumulate in the
recycling compartment, since the rate-limiting step in recycling is
transport from this location (36). To investigate to what extent the
perinuclear compartment containing ETA-GFP overlapped with
the recycling compartment, tetramethylrhodamine-labeled transferrin (Rh-Tf) was internalized into CHO cells cotransfected with
ETA-GFP and TfR. After 15 min of ET-mediated
internalization in the presence of Rh-Tf, we found extensive
colocalization of ETA-GFP and Rh-Tf in the pericentriolar
recycling compartment (Fig. 5, middle panels). ETA-GFP was observed intracellularly for up to 30 min after
the initiation of internalization and subsequently reappeared at the plasma membrane (see below). These data indicate that the recycling pathway is the dominant transport route of agonist-stimulated ETA receptors in CHO cells.
When CHO cells cotransfected with ETB-GFP and TfR were
investigated, we could not detect ETB-GFP in the recycling
compartment. Fig. 5 (lower panels) shows ETB-GFP
after 15 min of ET-mediated internalization in the presence of Rh-Tf.
The spread vesicular structures containing ETB-GFP do not
overlap with the central spot representing the Tf-containing recycling
compartment, indicating that the ETB receptor follows
another transport pathway in the cell. To investigate whether
ETB receptors were transported to lysosomes for
degradation, we studied ETB receptor internalization in
cells where the lysosomal compartments had been labeled with red
fluorescent dextran as described under "Experimental Procedures." After 15 min of internalization, there was no significant overlap between the ETB-containing vesicles and the dextran-labeled
lysosomes (Fig. 6, upper
panels), but after 90 min (middle panels) the vesicular pattern overlapped extensively (see Fig. 6C,
overlay). These findings suggest a degradative transport
pathway for the ETB-receptor, which is also consistent with
our observation that ETB-GFP did not reappear at the plasma
membrane in the presence of cycloheximide. Conversely,
ETA-GFP did not colocalize with lysosomes after prolonged ET-mediated internalization, but it was found to recycle back to the
plasma membrane independently of cycloheximide (Fig. 6, lower
panels). The intracellular trafficking pathways of
ETA-GFP and ETB-GFP were also analyzed in COS
cells, where the same characteristic differences in intracellular
routing were observed. As shown in Fig.
7, ETA-GFP colocalized with
transferrin in recycling endosomes (upper panels), whereas
ETB-GFP was found to enter LAMP-2 positive late endosomes
and lysosomes upon prolonged periods of internalization (middle
and lower panels).

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 6.
Lysosomal transport of ETB-GFP
and recycling of ETA-GFP. CHO cells expressing
ETB-GFP (upper and middle panels) or
ETA-GFP (lower panels) were incubated overnight
with Texas Red-conjugated dextran (0.2 mg/ml) to label the lysosomal
compartments. A 2-h chase without dextran was subsequently performed in
order to wash the probe out of early and late endosomes. During the
same time span, ET-1 was internalized for different time points as
described under "Experimental Procedures" before paraformaldehyde
fixation and fluorescence microscopy. ETB-GFP colocalized
with dextran-Texas Red-labeled lysosomes after 90 min (middle
panels; F is overlay) but not after 15 min
(upper panels; C is overlay) of ET-1
internalization. ETA-GFP did not colocalize with lysosomes
but reappeared at the plasma membrane after 90 min of ET-1
internalization (lower panels). Incubations were performed
in the presence of 10 µM cycloheximide to block de
novo synthesis of ET receptors.
|
|

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 7.
Intracellular trafficking of
ETA-GFP and ETB-GFP in COS cells.
Upper panels, A-C, after binding at
4 °C, ET-1 was internalized at 37 °C for 15 min in COS cells
expressing ETA-GFP as described under "Experimental
Procedures." At the start of the 15-min internalization period, Rh-Tf
was added to the cells for labeling of the recycling compartment (COS
cells express high levels of endogenous transferrin receptor). The
overlay (C) shows colocalization of ETA-GFP and
Rh-Tf in the recycling compartment. Middle and lower panels,
D-I, ET-1 was bound at 4 °C and internalized at 37 °C
for 10 min (middle panels, D-F) or 60 min
(lower panels, G-I) in COS cells expressing
ETB-GFP. After paraformaldehyde fixation and
permeabilization in 0.1% Triton X-100, late endosomes and lysosomes
were identified by immunostaining with a rabbit anti-human LAMP-2
antiserum and an Alexa594-conjugated goat anti-rabbit secondary
antibody. As shown, ETB-GFP did not overlap with
LAMP-2-positive compartments after 10 min of internalization
(middle panels; F is overlay).
However, distinct overlapping vesicles were identified after 60 min of
internalization (lower panels; I is
overlay).
|
|
Colocalization of ETA-GFP and ETB-GFP with
Rab5 in Early Endosomes--
Different members of the Rab family of
small GTPases have been shown to regulate distinct transport steps in
eucaryotic cells (37). Rab5 is localized to early endosomes and is a
rate-limiting component in membrane docking and fusion in the early
endocytic pathway (38). Rab5 Q79L is a GTPase-deficient mutant of Rab5 shown to increase homotypic fusion events between early endosomes and
retard transport out of these compartments (39). When
ETA-GFP and ETB-GFP were expressed
together with Rab5 Q79L in CHO cells, both receptors could be detected
in early endosomes (Fig. 8,
A-F). This experiment demonstrates that the intracellular
transport routes of both ETA-GFP and ETB-GFP go
through classical early endosomes before they separate into the
recycling pathway and the degradative pathway, respectively.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 8.
Colocalization of ETA-GFP and
ETB-GFP with Rab5 in early endosomes.
ETA-GFP (upper panels) or ETB-GFP
(lower panels) was expressed together with MycRab5 Q79L in
CHO cells using T7 vaccinia transfection. Five hours after
transfection, ET-1 was bound to the cells at 4 °C and subsequently
internalized for 30 min at 37 °C. The cells were fixed in
paraformaldehyde and permeabilized with 0.1% Triton X-100.
Overexpressed MycRab5 Q79L was identified by immunostaining with a
mouse monoclonal anti-Myc antibody and a rhodamine-conjugated goat
anti-mouse secondary antibody. Overlays (right) show
extensive colocalization of both ETA-GFP (C) and
ETB-GFP (F) with Rab5 in early endosomes.
|
|
 |
DISCUSSION |
The purpose of this study was to investigate the mechanisms of
internalization and intracellular trafficking of the ETA
and ETB receptors. We report for the first time the
involvement of arrestin and dynamin in the regulation of the ET
receptors, and we describe the previously unknown intracellular routes
of agonist-stimulated ETA and ETB receptors.
Both ETA and ETB receptors have been shown to
undergo agonist-dependent phosphorylation catalyzed by GRK.
In transfected HEK293 cells with overexpression of either
ARK1
(GRK2),
ARK2 (GRK3), or GRK5, all of the kinases have been shown to
phosphorylate agonist-activated ET receptors (20). However, the
specificity of the different GRK isoforms as to the substrates
ETA and ETB is not known. In the present study,
increased levels of
ARK1 did not augment internalization of the ET
receptors. However,
ARK1-CT substantially inhibited internalization
of the ETA receptor and to a lesser degree that of
ETB, demonstrating that at least ETA receptor
internalization is a
ARK1-mediated process. The less pronounced
effect of
ARK1-CT on internalization of ETB may be due
to phosphorylation of the ETB receptor by other
endogenously expressed receptor kinases in the CHO cells not subject to
competitive inhibition by
ARK1-CT. The lack of effect of
ARK1
wild type overexpression on internalization of the ETA
receptor indicates that
ARK1-mediated phosphorylation is not
rate-limiting for endocytosis in CHO cells, a cell line that displays
substantial levels of endogenously expressed
ARK1. Although both
receptor subtypes have cytoplasmic tails containing several serine and
threonine residues (40, 41), only ETB has motifs similar to
those previously demonstrated to be phosphorylated by GRK (42).
The ability of the
-arrestin-1 V53D and
-arrestin-2 V54D mutants
to inhibit both ETA and ETB receptor
internalization provides strong evidence that arrestin isoforms
regulate both receptor subtypes. These mutant arrestins compete with
endogenous arrestins in the cell by binding to clathrin, but they
display reduced affinity for the receptor (14). Our data therefore
demonstrate that the endogenous arrestins of the CHO cells contribute
to ET receptor endocytosis. However, our data do not indicate the
specific isoforms of arrestin involved in ET receptor regulation.
Arrestin appears to be a rate-limiting factor for internalization,
since overexpression of
-arrestin-1 or
-arrestin-2 resulted in a
significant increase in the rates of internalization of both the
ETA and the ETB receptors. Consistent with
these data, it has earlier been demonstrated that arrestin binding is
rate-limiting in the process of desensitization of the GPCR rhodopsin
in Drosophila (43).
As shown, the GTPase-deficient mutant dynamin K44A significantly
impaired ET receptor internalization. The involvement of dynamin is
considered to be a strong indicator for a
clathrin-dependent mechanism of internalization, although
evidence also indicates that dynamin may regulate other mechanisms of
endocytosis (44). However, our observations that potassium depletion of
CHO cells (31) or pretreatment in hyperosmotic sucrose (30) both
impaired internalization of ETA and ETB
receptors provide further evidence for the involvement of
clathrin-coated pits in endocytosis of these receptors. Previously,
Chun et al. (45) have proposed a role for caveolae in ET
receptor signaling and regulation, based on colocalization of
ETA receptors and caveolin in COS cells as assessed by
immunofluorescence. Although other GPCRs and related proteins involved
in signal transduction have also been shown to be localized to caveolae
(46, 47), the role of these subcellular structures in GPCR
internalization is still poorly understood.
Recently, it was shown that although internalized
2
adrenergic receptor colocalizes with the transferrin receptor in early endosomes, the receptors were located to different subpopulations of
clathrin-coated vesicles at earlier stages of endocytosis (48). We have
not investigated whether the ETA and ETB
receptors follow the same initial steps of endocytosis as the
transferrin receptor, but since both subtypes depend on classical
regulators of GPCRs, it is likely that they follow the same pathway as
the
2 adrenergic receptor into early endosomes. The
classical early endosome, also called the sorting endosome, is a
tubulovesicular structure where membrane proteins destined for
degradation are sorted away from recycling proteins and packed into
multivesicular bodies for further transport. Membrane proteins destined
for recycling are, on the other hand, rapidly transported from the
sorting endosome to the pericentriolar recycling compartment and are
subsequently directed back to the plasma membrane (49, 50). We found
that the transport routes of both the ETA and the
ETB receptors go through early endosomes, which is probably
the final common compartment of the two receptor subtypes.
The information for receptor targeting either to recycling or to
lysosomal degradation may reside in the cytoplasmic tail of the
receptors (51). Furthermore, data from a recent report suggest that the
presence of a cluster of serines in the tail of a GPCR appears to
mediate stable binding of arrestin and dictate internalized receptors
to lysosomes (52). According to the hypothesis presented in the latter
report, configurations of the cytoplasmic tail causing less stable
binding to arrestin lead to recycling and resensitization of the
receptor. Interestingly, the ETB receptor has a C-terminal
cluster of serines, which is not present in the tail of the
ETA receptor. Lysosomal targeting of the ETB
receptor could therefore be due to more stable interactions with
arrestin, while less stable binding to the tail of the ETA
receptor may lead this subtype to the recycling pathway. Consistent
with this hypothesis, it has been demonstrated that the ETA
receptor is not able to translocate
-arrestins to intracellular
compartments (53). The hypothesis that arrestin may target GPCRs to
lysosomes is also supported by ultrastructural data showing subcellular location of
-arrestin in multivesicular bodies (24).
ET-1 has been shown to dissociate very slowly from the ET receptors,
even at the low pH values corresponding to those of endosomes (pH
5.5-6.0) and lysosomes (pH 4.4-5.5) (21, 54, 55). Indeed, ET-1 has
been reported to remain bound to the ETA receptor after internalization (21). Thus, it has been hypothesized that
ligand-occupied ETA receptors may continue to activate the
G protein after endocytosis. In this respect, internalization of GPCRs
has been reported to be a prerequisite for transactivation of the
epidermal growth factor receptor (56). However, rapid receptor
endocytosis, resensitization, and recycling back to the plasma membrane
in order to initiate repeated cycles of signaling may also provide the
basis for a prolonged signal response. In fact, several reports have
shown that receptor internalization is obligatory for resensitization of GPCRs (57-59). Thus, the evidence provided in this report that ETA receptors are targeted to recycling may explain the
long lasting signal response observed through this receptor subtype.
ET-1 binds almost irreversibly to the ETB receptor at
physiological conditions (55). Thus, in context of our findings, direct transport of receptor-associated ET-1 to lysosomes for degradation could serve as the mechanism for clearance of plasma ET-1 via the
ETB receptor subtype. The high affinity between
ETB receptor and ET-1 ensures efficient capture of ET-1 at
the low (picomolar) levels in plasma but also implicates that the
receptor is simultaneously sacrificed in the clearance process. This
hypothesis correlates, however, well with the transient nature of
ETB receptor-mediated signaling. Moreover, we have shown in
the present study that the reappearance of ETB receptors at
the plasma membrane is sensitive to cycloheximide. This implicates that
the supply of de novo synthesized receptor molecules to the
cell surface would be a limiting factor for the ability of
ETB receptors to mediate efficient clearance of plasma
ET-1.
In conclusion, the present study demonstrates that the ET receptor
subtypes ETA and ETB are rapidly internalized
in an agonist-dependent manner, a process that appears to
depend on GRK, arrestin, dynamin, and clathrin. Furthermore, we have
demonstrated that internalized ETA and ETB
receptors both enter Rab5 positive early endosomes (sorting endosomes).
However, the two receptor subtypes are subsequently targeted to
different intracellular fates. While the ETA receptor follows a recycling pathway through the pericentriolar recycling compartment and reappears at the plasma membrane, the ETB
receptor is directed to lysosomes for degradation. Based on the data
presented in this study, we propose a model for the intracellular
trafficking pathways of the ET receptors, which is illustrated in the
schematic diagram of Fig. 9. The distinct
intracellular routes of ETA and ETB may explain
the characteristic physiological responses mediated by these receptors.
Thus, the rapid recycling of ETA may provide a basis for
the prolonged contractile response mediated through this receptor,
whereas lysosomal targeting of ETB supports current evidence suggesting a role for this receptor in clearance of ET from
the circulation. The aim of future studies will be to delineate the
mechanisms of the sorting process in early endosomes where the
intracellular routes of the two receptor subtypes separate.

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 9.
Model for regulation and intracellular
trafficking of the ET receptors. Based on the data of the present
study, a model for regulation and intracellular trafficking of the
ETA and ETB receptors is proposed. As indicated
in the diagram, both ETA and ETB are rapidly
internalized upon agonist stimulation, a process that depends on GRK,
arrestin, dynamin, and clathrin. Internalized ETA and
ETB are subsequently directed to Rab5 positive early
endosomes (sorting endosomes). However, from this location, the two
receptor subtypes are targeted to different intracellular fates.
Whereas the ETA receptor is directed to the pericentriolar
recycling compartment and subsequently reappears at the plasma
membrane, the ETB receptor is directed to lysosomes for
degradation.
|
|
 |
FOOTNOTES |
*
This work was supported by the MSD-Medinnova Cardiovascular
Research Fund and grants from the National Research Council and the
Norwegian Council on Cardiovascular Diseases.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Inst. of Surgical
Research/MSD-Cardiovascular Research Center, The National Hospital, 32 Pilestredet, N-0027 Oslo, Norway. Tel.: 47-22868522; Fax: 47-22111987; E-mail: havarda@rh.uio.no.
Published, JBC Papers in Press, March 30, 2000, DOI 10.1074/jbc.M000142200
 |
ABBREVIATIONS |
The abbreviations used are:
ET, endothelin;
GPCR, G protein-coupled receptor;
GRK, G protein-coupled receptor
kinase;
CHO, Chinese hamster ovary;
GFP, green fluorescent protein;
ARK,
-adrenergic receptor kinase;
Tf, transferrin;
TfR, transferrin receptor;
Rh-Tf, tetramethylrhodamine-labeled transferrin;
WT, wild type;
BSA, bovine serum albumin;
PBS, phosphate-buffered
saline.
 |
REFERENCES |
| 1.
|
Yanagisawa, M.,
Kurihara, H.,
Kimura, S.,
Tomobe, Y.,
Kobayashi, M.,
Mitsui, Y.,
Yazaki, Y.,
Goto, K.,
and Masaki, T.
(1988)
Nature
332,
411-415
|
| 2.
|
Sakurai, T.,
Yanagisawa, M.,
and Masaki, T.
(1992)
Trends Pharmacol. Sci.
13,
103-108
|
| 3.
|
Cramer, H.,
Muller-Esterl, W.,
and Schroeder, C.
(1997)
Biochemistry
36,
13325-13332
|
| 4.
|
Clozel, M.,
Gray, G. A.,
Breu, V.,
Loffler, B. M.,
and Osterwalder, R.
(1992)
Biochem. Biophys. Res. Commun.
186,
867-873
|
| 5.
|
Moreland, S.,
McMullen, D. M.,
Delaney, C. L.,
Lee, V. G.,
and Hunt, J. T.
(1992)
Biochem. Biophys. Res. Commun.
184,
100-106
|
| 6.
|
Yanagisawa, M.,
and Masaki, T.
(1989)
Biochem. Pharmacol.
38,
1877-1883
|
| 7.
|
Dupuis, J.,
Goresky, C. A.,
and Fournier, A.
(1996)
J. Appl. Phys.
81,
1510-1515
|
| 8.
|
Fukuroda, T.,
Fujikawa, T.,
Ozaki, S.,
Ishikawa, K.,
Yano, M.,
and Nishikibe, M.
(1994)
Biochem. Biophys. Res. Commun.
199,
1461-1465
|
| 9.
|
Kobayshi, T.,
Miyauchi, T.,
Sakai, S.,
Maeda, S.,
Yamaguchi, I.,
Goto, K.,
and Sugishita, Y.
(1998)
Life Sci.
62,
185-193
|
| 10.
|
Yu, S. S.,
Lefkowitz, R. J.,
and Hausdorff, W. P.
(1993)
J. Biol. Chem.
268,
337-341
|
| 11.
|
Krueger, K. M.,
Daaka, Y.,
Pitcher, J. A.,
and Lefkowitz, R. J.
(1997)
J. Biol. Chem.
272,
5-8
|
| 12.
|
Pippig, S.,
Andexinger, S.,
and Lohse, M. J.
(1995)
Mol. Pharmacol.
47,
666-676
|
| 13.
|
Freedman, N. J.,
and Lefkowitz, R. J.
(1996)
Rec. Prog. Horm. Res.
51,
319-353
|
| 14.
|
Ferguson, S. S.,
Downey, W. E., III,
Colapietro, A. M.,
Barak, L. S.,
Menard, L.,
and Caron, M. G.
(1996)
Science
271,
363-366
|
| 15.
|
Goodman, O. B., Jr.,
Krupnick, J. G.,
Santini, F.,
Gurevich, V. V.,
Penn, R. B.,
Gagnon, A. W.,
Keen, J. H.,
and Benovic, J. L.
(1996)
Nature
383,
447-450
|
| 16.
|
von Zastrow, M.,
and Kobilka, B. K.
(1992)
J. Biol. Chem.
267,
3530-3538
|
| 17.
|
Lefkowitz, R. J.
(1998)
J. Biol. Chem.
273,
18677-18680
|
| 18.
|
Ferguson, S. S.,
Zhang, J.,
Barak, L. S.,
and Caron, M. G.
(1998)
Life Sci.
62,
1561-1565
|
| 19.
|
Cyr, C. R.,
Rudy, B.,
and Kris, R. M.
(1993)
J. Biol. Chem.
268,
26071-26074
|
| 20.
|
Freedman, N. J.,
Ament, A. S.,
Oppermann, M.,
Stoffel, R. H.,
Exum, S. T.,
and Lefkowitz, R. J.
(1997)
J. Biol. Chem.
272,
17734-17743
|
| 21.
|
Chun, M.,
Lin, H. Y.,
Henis, Y. I.,
and Lodish, H. F.
(1995)
J. Biol. Chem.
270,
10855-10860
|
| 22.
|
Sakamoto, A.,
Yanagisawa, M.,
Sawamura, T.,
Enoki, T.,
Ohtani, T.,
Sakurai, T.,
Nakao, K.,
Toyo-oka, T.,
and Masaki, T.
(1993)
J. Biol. Chem.
268,
8547-8553
|
| 23.
|
van der Bliek, A. M.,
Redelmeier, T. E.,
Damke, H.,
Tisdale, E. J.,
Meyerowitz, E. M.,
and Schmid, S. L.
(1993)
J. Cell Biol.
122,
553-563
|
| 24.
|
Attramadal, H.,
Arriza, J. L.,
Aoki, C.,
Dawson, T. M.,
Codina, J.,
Kwatra, M. M.,
Snyder, S. H.,
Caron, M. G.,
and Lefkowitz, R. J.
(1992)
J. Biol. Chem.
267,
17882-17890
|
| 25.
|
Stenmark, H.,
Bucci, C.,
and Zerial, M.
(1995)
Methods Enzymol.
257,
155-164
|
| 26.
|
Elshourbagy, N. A.,
Korman, D. R.,
Wu, H. L.,
Sylvester, D. R.,
Lee, J. A.,
Nuthalaganti, P.,
Bergsma, D. J.,
Kumar, C. S.,
and Nambi, P.
(1993)
J. Biol. Chem.
268,
3873-3879
|
| 27.
|
Daaka, Y.,
Pitcher, J. A.,
Richardson, M.,
Stoffel, R. H.,
Robishaw, J. D.,
and Lefkowitz, R. J.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
2180-2185
|
| 28.
|
Laporte, S. A.,
Oakley, R. H.,
Zhang, J.,
Holt, J. A.,
Ferguson, S. S.,
Caron, M. G.,
and Barak, L. S.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
3712-3717
|
| 29.
|
Damke, H.,
Baba, T.,
Warnock, D. E.,
and Schmid, S. L.
(1994)
J. Cell Biol.
127,
915-934
|
| 30.
|
Heuser, J. E.,
and Anderson, R. G.
(1989)
J. Cell Biol.
108,
389-400
|
| 31.
|
Larkin, J. M.,
Brown, M. S.,
Goldstein, J. L.,
and Anderson, R. G.
(1983)
Cell
33,
273-285
|
| 32.
|
Okamoto, Y.,
Ninomiya, H.,
Tanioka, M.,
Sakamoto, A.,
Miwa, S.,
and Masaki, T.
(1997)
J. Biol. Chem.
272,
21589-21596
|
| 33.
|
Yamashiro, D. J.,
Tycko, B.,
Fluss, S. R.,
and Maxfield, F. R.
(1984)
Cell
37,
789-800
|
| 34.
|
Mayor, S.,
Presley, J. F.,
and Maxfield, F. R.
(1993)
J. Cell Biol.
121,
1257-1269
|
| 35.
|
Donaldson, J. G.,
Kahn, R. A.,
Lippincott-Schwartz, J.,
and Klausner, R. D.
(1991)
Science
254,
1197-1199
|
| 36.
|
Presley, J. F.,
Mayor, S.,
Dunn, K. W.,
Johnson, L. S.,
McGraw, T. E.,
and Maxfield, F. R.
(1993)
J. Cell Biol.
122,
1231-1241
|
| 37.
|
Olkkonen, V. M.,
and Stenmark, H.
(1997)
Int. Rev. Cytol.
176,
1-85
|
| 38.
|
Gorvel, J. P.,
Chavrier, P.,
Zerial, M.,
and Gruenberg, J.
(1991)
Cell
64,
915-925
|
| 39.
|
Stenmark, H.,
Parton, R. G.,
Steele-Mortimer, O.,
Lutcke, A.,
Gruenberg, J.,
and Zerial, M.
(1994)
EMBO J.
13,
1287-1296
|
| 40.
|
Sakamoto, A.,
Yanagisawa, M.,
Sakurai, T.,
Takuwa, Y.,
Yanagisawa, H.,
and Masaki, T.
(1991)
Biochem. Biophys. Res. Commun.
178,
656-663
|
| 41.
|
Hosoda, K.,
Nakao, K.,
Hiroshi, A.,
Suga, S.,
Ogawa, Y.,
Mukoyama, M.,
Shirakami, G.,
Saito, Y.,
Nakanishi, S.,
and Imura, H.
(1991)
FEBS Lett.
287,
23-26
|
| 42.
|
Fredericks, Z. L.,
Pitcher, J. A.,
and Lefkowitz, R. J.
(1996)
J. Biol. Chem.
271,
13796-13803
|
| 43.
|
Ranganathan, R.,
and Stevens, C. F.
(1995)
Cell
81,
841-848
|
| 44.
|
Oh, P.,
McIntosh, D. P.,
and Schnitzer, J. E.
(1998)
J. Cell Biol.
141,
101-114
|
| 45.
|
Chun, M.,
Liyanage, U. K.,
Lisanti, M. P.,
and Lodish, H. F.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
11728-11732
|
| 46.
|
Roettger, B. F.,
Rentsch, R. U.,
Pinon, D.,
Holicky, E.,
Hadac, E.,
Larkin, J. M.,
and Miller, L. J.
(1995)
J. Cell Biol.
128,
1029-1041
|
| 47.
|
Raposo, G.,
Dunia, I.,
Marullo, S.,
Andre, C.,
Guillet, J. G.,
Strosberg, A. D.,
Benedetti, E. L.,
and Hoebeke, J.
(1987)
Biol. Cell
60,
117-123
|
| 48.
|
Cao, T. T.,
Mays, R. W.,
and von Zastrow, M.
(1998)
J. Biol. Chem.
273,
24592-24602
|
| 49.
|
Dunn, K. W.,
McGraw, T. E.,
and Maxfield, F. R.
(1989)
J. Cell Biol.
109,
3303-3314
|
| 50.
|
Ghosh, R. N.,
and Maxfield, F. R.
(1995)
J. Cell Biol.
128,
549-561
|
| 51.
|
Trejo, J.,
and Coughlin, S. R.
(1999)
J. Biol. Chem.
274,
2216-2224
|
| 52.
|
Oakley, R. H.,
Laporte, S. A.,
Holt, J. A.,
Barak, L. S.,
and Caron, M. G.
(1999)
J. Biol. Chem.
274,
32248-32257
|
| 53.
|
Zhang, J.,
Barak, L. S.,
Anborgh, P. H.,
Laporte, S. A.,
Caron, M. G.,
and Ferguson, S. S.
(1999)
J. Biol. Chem.
274,
10999-11006
|
| 54.
|
Mellman, I.
(1992)
J. Exp. Biol.
172,
39-45
|
| 55.
|
Takasuka, T.,
Adachi, M.,
Miyamoto, C.,
Furuichi, Y.,
and Watanabe, T.
(1992)
J. Biochem. (Tokyo)
112,
396-400 |